|
41 Companies |
|
50 Products |
|
50 Products |
|
53 Mechanisms of Action |
|
1 Trial |
|
299 News |
|
| «123456» |
- dexamethasone / Generic mfg.
Trial primary completion date: Dexamethasone Irrigation of the Parotid Glands in Primary Sj (clinicaltrials.gov) - Jun 25, 2015
P2, N=14, Enrolling by invitation, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Trial primary completion date: Jun 2015 --> Jun 2017
- dovitinib (TKI258) / Novartis, Oncoheroes
Trial primary completion date, Metastases: DOVE: A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (clinicaltrials.gov) - Jun 11, 2015
P2, N=21, Active, not recruiting, Sponsor: Ontario Clinical Oncology Group (OCOG)
Trial primary completion date: Jun 2015 --> Jun 2017 Trial primary completion date: Jul 2014 --> Jul 2015
- || gefitinib / Generic mfg.
Trial primary completion date, Metastases: Iressa Study in Patients With Salivary Gland Cancer (clinicaltrials.gov) - Jun 11, 2015
P2, N=80, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2014 --> Jul 2015 Trial primary completion date: Nov 2015 --> Nov 2016
- | prezalumab (AMG 557) / Amgen, AstraZeneca
Trial initiation date, Trial primary completion date: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Jun 11, 2015
P2, N=42, Not yet recruiting, Sponsor: MedImmune LLC
Trial primary completion date: Nov 2015 --> Nov 2016 Initiation date: Jan 2015 --> May 2015 | Trial primary completion date: Mar 2015 --> Feb 2017
- Enrollment open: Examining the Immunological Process of Autoimmune Patients (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=200, Recruiting, Sponsor: University of Florida
Initiation date: Jan 2015 --> May 2015 | Trial primary completion date: Mar 2015 --> Feb 2017 Not yet recruiting --> Recruiting
- tamoxifen / Generic mfg., exemestane / Generic mfg.
Trial completion, Trial primary completion date, HEOR: Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors (clinicaltrials.gov) - May 27, 2015
P=N/A, N=58, Completed, Sponsor: University of Michigan
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2013
- dexamethasone / Generic mfg.
Enrollment status, Enrollment change: Dexamethasone Irrigation of the Parotid Glands in Primary Sj (clinicaltrials.gov) - May 12, 2015
P2, N=14, Enrolling by invitation, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Active, not recruiting --> Completed | Trial primary completion date: Aug 2012 --> Aug 2013 Recruiting --> Enrolling by invitation | N=20 --> 14
- gefitinib / Generic mfg., docetaxel / Generic mfg.
Trial termination, Metastases: Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer (clinicaltrials.gov) - May 7, 2015
P3, N=270, Terminated, Sponsor: National Cancer Institute (NCI)
Recruiting --> Enrolling by invitation | N=20 --> 14 Completed --> Terminated; It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results.
- Recentin (cediranib) / AstraZeneca
Trial completion, Enrollment change, Monotherapy, Metastases: Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer (clinicaltrials.gov) - May 5, 2015
P2, N=6, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Terminated; It was unlikely that the primary endpoint would be reached based on the fifth interim analysis results. Active, not recruiting --> Completed | N=19 --> 6
- Trial primary completion date: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
Active, not recruiting --> Completed | N=19 --> 6 Trial primary completion date: Nov 2015 --> Apr 2016
- |||||| Enrollment open, Trial initiation date, Trial primary completion date: Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (clinicaltrials.gov) - Apr 14, 2015
P3, N=1560, Recruiting, Sponsor: The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Trial primary completion date: Nov 2015 --> Apr 2016 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Apr 2015 --> Nov 2015
- cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=41, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Feb 2015 | Trial primary completion date: Apr 2015 --> Nov 2015 Suspended --> Active, not recruiting
- timbetasin ophthalmic (RGN-259) / ReGenTree
Trial completion: Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye (clinicaltrials.gov) - Apr 9, 2015
P2, N=18, Completed, Sponsor: Michigan Cornea Consultants, PC
Suspended --> Active, not recruiting Recruiting --> Completed
- ||||| Priorix (MMR vaccine) / GSK
Enrollment closed: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older (clinicaltrials.gov) - Apr 1, 2015
P3, N=1000, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Trial completion: Green Tea Lozenges for the Management of Dry Mouth (clinicaltrials.gov) - Mar 18, 2015
P1/2, N=60, Completed, Sponsor: Georgia Regents University
Recruiting --> Active, not recruiting Recruiting --> Completed
- cisplatin / Generic mfg.
Trial suspension, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Mar 14, 2015
P1, N=15, Suspended, Sponsor: Virginia Commonwealth University
Recruiting --> Completed Recruiting --> Suspended
- Halaven (eribulin mesylate) / Eisai
Trial primary completion date, Metastases: Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer (clinicaltrials.gov) - Mar 7, 2015
P2, N=29, Recruiting, Sponsor: University of Washington
Recruiting --> Suspended Trial primary completion date: Nov 2014 --> Nov 2015
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Trial completion, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Mar 7, 2015
P1, N=13, Completed, Sponsor: University of Washington
Trial primary completion date: Nov 2014 --> Nov 2015 Active, not recruiting --> Completed
- Orencia (abatacept) / BMS
Enrollment change, Trial withdrawal: Abatacept for Patients With Inflammatory Arthritis Associated With Sj (clinicaltrials.gov) - Feb 5, 2015
P2, N=0, Withdrawn, Sponsor: Qingping Yao
Active, not recruiting --> Completed N=15 --> 0 | Recruiting --> Withdrawn
- Enrollment open, Surgery: Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery (clinicaltrials.gov) - Jan 30, 2015
P=N/A, N=5, Recruiting, Sponsor: Domain Surgical, Inc.
N=15 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial completion, Enrollment change: Incobotulinum Toxin A (Xeomin (clinicaltrials.gov) - Jan 28, 2015
P2, N=10, Completed, Sponsor: Beth Israel Deaconess Medical Center
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 10
- Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap
Trial primary completion date: ALS-TOX: Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea (clinicaltrials.gov) - Jan 17, 2015
P2, N=90, Recruiting, Sponsor: Hospices Civils de Lyon
Recruiting --> Completed | N=20 --> 10 Trial primary completion date: Aug 2014 --> Aug 2015
- Trial primary completion date: Multi-Colored Placido Disk Viability (clinicaltrials.gov) - Jan 12, 2015
P=N/A, N=20, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Aug 2014 --> Aug 2015 Trial primary completion date: Jul 2014 --> Sep 2015
- | prezalumab (AMG 557) / Amgen, AstraZeneca
New P2 trial: A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sj (clinicaltrials.gov) - Jan 8, 2015
P2, N=42, Not yet recruiting, Sponsor: MedImmune LLC
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion, Trial primary completion date: Rituximab in IgG4-RD: A Phase 1-2 Trial (clinicaltrials.gov) - Jan 8, 2015
P1/2, N=30, Completed, Sponsor: Massachusetts General Hospital
Trial primary completion date: Jul 2014 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jan 2014
- Enrollment change, Trial termination, Trial primary completion date, HEOR: TOQUAL: Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract (clinicaltrials.gov) - Dec 19, 2014
P2, N=11, Terminated, Sponsor: Centre Francois Baclesse
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jan 2014 N=44 --> 11 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Dec 2014; lack of recrutment
- Trial completion: TOYOTA: Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome (clinicaltrials.gov) - Dec 19, 2014
P=N/A, N=14, Completed, Sponsor: University of Waterloo
N=44 --> 11 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Dec 2014; lack of recrutment Recruiting --> Completed
- ||| Clinical: Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases (clinicaltrials.gov) - Dec 16, 2014
P=N/A, N=120, Completed, Sponsor: Dental Innovation Foundation Under Royal Patronage
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: MAESTRO HN: Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy (clinicaltrials.gov) - Dec 12, 2014
P2, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Trial primary completion date: Jan 2015 --> Jan 2016
- Trial completion: Making Decisions About the Measles-Mumps-Rubella Vaccine (clinicaltrials.gov) - Dec 10, 2014
P=N/A, N=79, Completed, Sponsor: University of Michigan
Trial primary completion date: Jan 2015 --> Jan 2016 Active, not recruiting --> Completed
- Surgery: Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery (clinicaltrials.gov) - Nov 17, 2014
P=N/A, N=5, Not yet recruiting, Sponsor: Domain Surgical, Inc.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck (clinicaltrials.gov) - Nov 11, 2014
P1, N=13, Active, not recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014
- |||| Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: SIAXI: Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (clinicaltrials.gov) - Nov 5, 2014
P3, N=180, Recruiting, Sponsor: Merz Pharmaceuticals GmbH
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jun 2014 Trial primary completion date: Apr 2015 --> Jul 2015
- Enrollment change: Effects of Sustained Reading on the Ocular Surface (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=40, Recruiting, Sponsor: University of Rochester
Trial primary completion date: Apr 2015 --> Jul 2015 N=30 --> 40
- Enrollment change, Trial initiation date, Trial withdrawal: SHOTGUN: Saliva, Hyperbaric Oxygen Therapy, & Gland Function: A Prospective Study (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=0, Withdrawn, Sponsor: Loma Linda University
N=30 --> 40 N=78 --> 0 | Initiation date: May 2012 --> Aug 2015 | Not yet recruiting --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Enrollment closed, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Oct 15, 2014
P2, N=76, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=78 --> 0 | Initiation date: May 2012 --> Aug 2015 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- cisplatin / Generic mfg.
Trial primary completion date, Metastases: Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC (clinicaltrials.gov) - Oct 11, 2014
P1, N=15, Recruiting, Sponsor: Virginia Commonwealth University
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Jan 2017
- Enrollment open: TOYOTA: Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=14, Recruiting, Sponsor: University of Waterloo
Trial primary completion date: Jan 2015 --> Jan 2017 Not yet recruiting --> Recruiting
- Trial completion, Enrollment change, Trial primary completion date: The Effect of Honey on Xerostomia and Oral Mucositis (clinicaltrials.gov) - Oct 10, 2014
P2, N=72, Completed, Sponsor: Cyprus University of Technology
Not yet recruiting --> Recruiting Recruiting --> Completed | N=60 --> 72 | Trial primary completion date: Jan 2013 --> Sep 2014
- dasatinib / Generic mfg.
Trial completion, Metastases: Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Oct 2, 2014
P2, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=60 --> 72 | Trial primary completion date: Jan 2013 --> Sep 2014 Terminated --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Phase classification: P1/2 --> P1
- erlotinib / Generic mfg.
Trial termination: Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung (clinicaltrials.gov) - Sep 15, 2014
P1, N=60, Terminated, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P1 Active, not recruiting --> Terminated
- selenomethionine (SLM) / University of Iowa, Holden Comprehensive Cancer Center
Trial termination, Metastases: Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy (clinicaltrials.gov) - Aug 22, 2014
P2, N=18, Terminated, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Terminated Completed --> Terminated; Due to a lack of funding
- || metoclopramide / Generic mfg., clozapine / Generic mfg.
New P3 trial: Metoclopramide as Treatment of Clozapine-induced Hypersalivation (clinicaltrials.gov) - Aug 21, 2014
P3, N=61, Completed, Sponsor: Beersheva Mental Health Center
- |||||| Priorix (MMR vaccine) / GSK
Enrollment open, Trial primary completion date: Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older (clinicaltrials.gov) - Aug 11, 2014
P3, N=1000, Recruiting, Sponsor: GlaxoSmithKline
Completed --> Terminated; Due to a lack of funding Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Apr 2015
- baminercept (BG 9924) / Biogen
Enrollment closed, Trial primary completion date: Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sj (clinicaltrials.gov) - Aug 8, 2014
P2, N=72, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting | Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014
- Trial initiation date: Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=64, Completed, Sponsor: Jinyang Li
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2014 --> Dec 2014 Initiation date: Sep 2013 --> Mar 2013
- Xeomin (incobotulinumtoxinA) / Merz Pharma
Trial primary completion date: Incobotulinum Toxin A (Xeomin (clinicaltrials.gov) - Jul 18, 2014
P2, N=20, Recruiting, Sponsor: Beth Israel Deaconess Medical Center
Initiation date: Sep 2013 --> Mar 2013 Trial primary completion date: Nov 2013 --> Oct 2014
- | Trial completion: An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness (clinicaltrials.gov) - Jul 15, 2014
P1/2, N=24, Completed, Sponsor: Parion Sciences
Trial primary completion date: Nov 2013 --> Oct 2014 Active, not recruiting --> Completed
- MK-2206 / Merck (MSD)
Enrollment change, Metastases: Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma (clinicaltrials.gov) - Jul 14, 2014
P2, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=15 --> 18